Polymun Scientific Immunbiologische Forschung GmbH

The core activities of Polymun are contract development and GMP manufacturing of biopharmaceuticals as well as liposomal formulations of APIs and vaccine antigens – for clinical studies and the market. Revenues are invested in own R&D projects and the further development of technology platforms. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license thus meeting all EU for drug manufacturing. In addition, Polymun’s facility is accepted by the US FDA.